Chemours Company (The) (CC) Shares Sold by Systematic Financial Management LP
Systematic Financial Management LP trimmed its position in shares of Chemours Company (The) (NYSE:CC) by 55.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,216 shares of the specialty chemicals company’s stock after selling 54,940 shares during the quarter. Systematic Financial Management LP’s holdings in Chemours Company (The) were worth $1,677,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Financial Architects Inc boosted its holdings in Chemours Company (The) by 1,230.3% during the 2nd quarter. Financial Architects Inc now owns 2,940 shares of the specialty chemicals company’s stock valued at $111,000 after acquiring an additional 2,719 shares during the period. Benjamin F. Edwards & Company Inc. raised its position in Chemours Company (The) by 2,138.8% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 3,112 shares of the specialty chemicals company’s stock valued at $118,000 after purchasing an additional 2,973 shares in the last quarter. Schroder Investment Management Group acquired a new stake in Chemours Company (The) in the 1st quarter valued at about $156,000. Smithfield Trust Co. raised its position in Chemours Company (The) by 521.4% in the 2nd quarter. Smithfield Trust Co. now owns 4,791 shares of the specialty chemicals company’s stock valued at $182,000 after purchasing an additional 4,020 shares in the last quarter. Finally, Alps Advisors Inc. acquired a new stake in Chemours Company (The) in the 2nd quarter valued at about $202,000. Institutional investors own 72.90% of the company’s stock.
Shares of Chemours Company (NYSE CC) opened at 50.36 on Friday. The firm has a market cap of $9.31 billion, a price-to-earnings ratio of 32.96 and a beta of 3.64. The stock’s 50 day moving average price is $49.94 and its 200 day moving average price is $42.84. Chemours Company has a 12 month low of $14.07 and a 12 month high of $51.59.
Chemours Company (The) (NYSE:CC) last released its quarterly earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.02. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. The business had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter in the previous year, the firm posted $0.27 earnings per share. The company’s revenue was up 14.8% compared to the same quarter last year. Equities research analysts predict that Chemours Company will post $3.51 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Thursday, August 17th were paid a $0.03 dividend. This represents a $0.12 annualized dividend and a dividend yield of 0.24%. The ex-dividend date of this dividend was Tuesday, August 15th. Chemours Company (The)’s dividend payout ratio (DPR) is 8.11%.
A number of equities research analysts have issued reports on the company. Zacks Investment Research lowered Chemours Company (The) from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 12th. UBS AG raised Chemours Company (The) from a “sell” rating to a “neutral” rating and increased their price target for the company from $36.00 to $50.00 in a research report on Monday, August 7th. Jefferies Group LLC increased their price target on Chemours Company (The) to $60.00 and gave the company a “buy” rating in a research report on Thursday, August 3rd. BidaskClub raised Chemours Company (The) from a “hold” rating to a “buy” rating in a research report on Thursday, August 24th. Finally, J P Morgan Chase & Co increased their price target on Chemours Company (The) to $55.00 and gave the company an “overweight” rating in a research report on Friday, August 4th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $51.50.
TRADEMARK VIOLATION NOTICE: This article was posted by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/09/17/chemours-company-the-cc-shares-sold-by-systematic-financial-management-lp.html.
In related news, VP Amy Trojanowski sold 2,500 shares of the business’s stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $46.03, for a total value of $115,075.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider E Bryan Snell sold 13,000 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $49.35, for a total value of $641,550.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,837 shares of company stock worth $1,865,603. Insiders own 1.14% of the company’s stock.
Chemours Company (The) Company Profile
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.
Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.